On August 31, 2026 AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, reported that four abstracts highlighting clinical and nonclinical data supporting the development of epetraborole, a novel boron-containing oral candidate for the treatment of polycythemia vera (PV), will be presented at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting, taking place September 9-12, 2026, at the George R. Brown Convention Center in Houston, Texas.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"These abstracts provide insights into the potential beneficial hematological effects of epetraborole across both clinical and nonclinical studies and strengthen our understanding of the exposure-response relationships that we believe support its development in polycythemia vera," said George H. Talbot, M.D. Co-Founder and Senior Medical Advisor of AN2 Therapeutics.

Key Highlights:

Clinical and nonclinical studies demonstrated potential beneficial effects of epetraborole on erythropoiesis and hemoglobin-related parameters.
Data further characterized the hematological and safety profile of epetraborole across healthy volunteers, non-PV patients, and nonhuman primate models.
Exposure-response relationships observed in nonhuman primates were predictive of effects subsequently observed in humans, supporting the translational relevance of these models.
Collectively, the findings support the ongoing clinical development of epetraborole as a potential oral treatment for PV.
SOHO 2026 Abstracts:

Poster Number

Title

MPN-1041

Epetraborole Demonstrates an Exposure-Dependent Effect on Erythropoiesis in Healthy Subjects

MPN-1076

Hematological and Safety Profile of Epetraborole in a Non-Polycythemia Vera Patient Population

MPN-1082

Exposure-Response Analyses of Hemoglobin Changes During Epetraborole Administration to Nonhuman Primates Predict Human Exposure-Response Relationships

MPN-1106

Hematological Profile in Nonhuman Primates of Epetraborole, a Novel Boron-Containing Candidate for Oral Treatment of Polycythemia Vera

Copies of the abstracts will be available on the Presentations and Publications section of the AN2 Therapeutics website at the following link: View Source

(Press release, AN2 Therapeutics, AUG 31, 2026, View Source [SID1234670466])